Screener
Cullinan Therapeutics, Inc. CGEM Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$53.7M+23.3% | -$49.66M-2.4% | -$50.71M-6.4% | -$50.61M-24.8% | -$70.06M-66.7% | ||
| $79K+2.6% | $79K+3.9% | $79K+2.6% | $79K+3.9% | $77K0.0% | ||
| $8.45M-14.6% | $7.62M-18.8% | $7.31M-24.1% | $9.47M+0.4% | $9.89M-6.1% | ||
| -$38.22M+33.7% | -$46.05M-6.7% | -$38.11M-4.0% | -$36.88M-8.0% | -$57.61M-58.7% | ||
| $40.68M-23.8% | $32.41M-11.9% | $22.39M— | $67.39M— | $53.4M+129% | ||
| $1.1M+195% | $380K— | $715K-54.8% | $0-100% | $373K-99.9% | ||
| —— | -$13.25M-109% | —— | $30.52M+336% | -$3.84M-109% |
FAQ
- How much cash does Cullinan Therapeutics, Inc. generate?
- Cullinan Therapeutics, Inc. (CGEM) generated -$159.3M in operating cash flow over the trailing twelve months.
- Where does Cullinan Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.